Every 10-Q that Connect Biopharma Holdings Limited (CNTB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CNTB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CNTB filings page.
Connect Biopharma Holdings Limited, a clinical-stage company focused on asthma and COPD, reported higher collaboration revenue but larger losses for the three and six months ended June 30, 2026. License and collaboration revenue rose to $2.8 million for the quarter and $2.9 million year‑to‑date, driven mainly by a regulatory milestone from the Simcere Greater China partnership, partially offset by development cost sharing.
Research and development expense increased to $16.3 million for the quarter and $31.3 million year‑to‑date, reflecting expanded rademikibart clinical programs in acute asthma and COPD. General and administrative expense declined to $4.1 million for the quarter and $8.8 million year‑to‑date, primarily from lower professional fees.
The company recorded a net loss of $17.3 million for the quarter and $36.7 million for the first half of 2026, with operating cash outflows of $31.9 million. Cash, cash equivalents and short‑term investments totaled $31.5 million as of June 30, 2026, including net proceeds of $18.6 million from a March 2026 private placement of 6,130,000 ordinary shares. Management believes these resources will meet anticipated cash requirements for at least one year from the report filing date.
Connect Biopharma Holdings Limited reported a larger quarterly loss as it increased investment in its lead respiratory drug candidate rademikibart and bolstered its cash balance through a private placement. For the three months ended March 31, 2026, net loss widened to $19.4 million from $10.3 million a year earlier, driven mainly by higher rademikibart-related research and development spending of $15.0 million versus $6.6 million in 2025.
The company generated $0.2 million in license and collaboration revenue from its Simcere agreement in Greater China and ended the quarter with $46.0 million in cash and cash equivalents. Operating cash outflow was $16.0 million. In March 2026, Connect raised $20.2 million in gross proceeds (estimated net $18.6 million) via a private placement of 6.13 million ordinary shares, increasing total shares outstanding to about 62.96 million as of April 30, 2026. Management believes existing cash will fund operations for at least one year from the filing date.
Connect Biopharma (CNTB) reported Q3 2025 results with license and collaboration revenue of $16,000 and total operating expenses of $17.7 million, driven by research and development of $11.1 million and general and administrative of $6.6 million. The company posted a net loss of $17.2 million (basic and diluted loss per share $0.31). For the nine months, revenue was $64,000 and net loss was $40.4 million.
Cash, cash equivalents and short-term investments were $54.8 million as of September 30, 2025. Management believes these resources will fund anticipated needs for at least one year from the filing date. Total shareholders’ equity was $55.4 million.
In September, CNTB terminated its ADR program; ADRs were exchanged one-for-one into ordinary shares, which now trade on Nasdaq under “CNTB.” The company presented rademikibart data at ERS 2025 and is running Phase 2 studies in acute exacerbations of asthma and COPD, with topline data expected in the first half of 2026. As of October 31, 2025, 55,903,513 ordinary shares were outstanding.
Connect Biopharma (CNTB) reported a swing to loss as the company recorded a $23.2 million net loss for the six months ended June 30, 2025, compared with net income of $6.2 million in the prior-year period. Revenue from the Simcere license fell sharply to $48,000 in both the three- and six-month periods from $24.1 million a year earlier, driven by prior upfront and milestone recognition in 2024. Rademikibart progress remains central: the company presented clinical and preclinical data showing rapid FEV1 improvement and reduced exacerbations and reports that its China collaborator submitted an NDA for atopic dermatitis; Connect is eligible for up to $110 million in remaining milestones plus royalties.
Liquidity tightened: cash, cash equivalents and short-term investments totaled $71.8 million at quarter end and management states this is sufficient to meet anticipated cash requirements for at least one year from the filing. Operating cash use increased to $22.6 million for the six months, reflecting higher R&D as Phase 2 acute‑exacerbation trials were initiated and ongoing program investment continued.